J. Goldman & Co LP Acquires New Position in Alumis Inc. $ALMS

J. Goldman & Co LP acquired a new position in Alumis Inc. (NASDAQ:ALMS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 25,846 shares of the company’s stock, valued at approximately $727,000.

Other hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after buying an additional 4,926 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after purchasing an additional 11,949 shares during the period. Jane Street Group LLC acquired a new position in Alumis during the 1st quarter worth about $111,000. Rhumbline Advisers boosted its stake in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Alumis by 163.2% in the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock worth $3,504,000 after acquiring an additional 724,133 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have weighed in on ALMS. Morgan Stanley restated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research note on Friday, May 15th. Chardan Capital raised their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. HC Wainwright reissued a “neutral” rating and issued a $25.00 target price on shares of Alumis in a report on Friday, August 14th. Wells Fargo & Company increased their price target on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Guggenheim raised their price objective on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $23.62 on Thursday. Alumis Inc. has a one year low of $3.76 and a one year high of $31.35. The firm has a market capitalization of $3.06 billion, a P/E ratio of -6.12 and a beta of -0.69. The company’s fifty day moving average is $26.58 and its two-hundred day moving average is $25.13.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The company had revenue of $1.66 million during the quarter, compared to analysts’ expectations of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. On average, sell-side analysts forecast that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO John R. Schroer sold 3,282 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $86,546.34. Following the completion of the transaction, the chief financial officer directly owned 24,718 shares of the company’s stock, valued at $651,813.66. This trade represents a 11.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sanam Pangali sold 5,000 shares of Alumis stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider directly owned 11,111 shares of the company’s stock, valued at approximately $311,108. This represents a 31.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 19,953 shares of company stock valued at $534,311 in the last 90 days. 33.70% of the stock is owned by corporate insiders.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.